The burden of cardiovascular-kidney-metabolic (CKM) comorbidities among adults with gout is high, noted Chio Yokose, MD, MSc, ...

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has ...

Sobi agrees to buy Arthrosi Therapeutics for up to $1.5 billion, adding the Phase 3 gout asset pozdeutinurad to expand its ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...

Gout is the most common form of inflammatory arthritis, with worldwide prevalence of approximately four%. The accumulation of ...

A new study published in The Journal of Rheumatology showed that despite using lower dosages, febuxostat more successfully ...

Researchers identified 8 immune cell phenotypes that demonstrated causal associations with gout risk: 5 protective and 3 linked to increased risk. Interactions between immune cell phenotypes and gut ...

AN ANCIENT herbal remedy could reduce pain and inflammation and limit damage caused by arthritis, a new study showed. Its ...

Researchers have used CRISPR to switch back on a gene that vanished from the human lineage roughly 20 million years ago, ...

Half of the world's population will go through menopause, and more women are spreading awareness about this life stage.

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.

Scilex Holding Company ('Scilex” or the 'Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ...